Buprenorphine HCl, 0.3 mg/mL recall — Par Health Usa, LLC (Class II)
Par Health Usa, LLC is recorded by the U.S. Food and Drug Administration (FDA) as recalling Buprenorphine HCl, 0.3 mg/mL — a Class II recall, initiated 2026-06-12 and posted to the FDA enforcement report on 2026-06-24, under recall number D-0596-2026. Status Ongoing, with no termination date on the record. The reason the FDA record carries is, verbatim: “Crystallization; identified as Buprenorphine free base”. From the product description, the form is injection, the strengths given are 0.3 mg/mL and 1 mL and it is marked Rx only. 1 National Drug Code number is printed in the record: 42023-179-05. Distribution is recorded as “Nationwide in the USA” — Nationwide (US), with the recalling firm on record in MI, United States. It is the only recall number the FDA has filed under event ID 99237. Values are reproduced from the linked openFDA report; regulatory information, not medical advice.
Regulatory snapshot
| Recall number | D-0596-2026 |
|---|---|
| FDA event ID | 99237 |
| Classification | Class II (intermediate regulatory tier) |
| Status | Ongoing |
| Recalling firm | Par Health Usa, LLC |
| Recall initiated | 2026-06-12 |
| Reported by FDA | 2026-06-24 |
| Report lag | 12 days from initiation to report |
| Distribution | Nationwide in the USA. — Nationwide (US) |
| Firm location on record | MI, United States |
| Product description (source) | Buprenorphine HCl, CIII, Injection, 0.3 mg/mL, 5 x 1 mL Single Dose Vials per Carton, Rx Only, For Intramuscular or Intravenous use, Manufactured for: Endo USA, Malvern, PA 19355, NDC 42023-179-05 |
Reason reported by FDA
Crystallization; identified as Buprenorphine free base
6 words from the enforcement report field reason_for_recall, reproduced without edit — the firm's own wording, not an assessment.
Product identifiers in this record
6 identifying values matched by exact pattern in the 31-word product description above; each is a literal substring of it.
| Product named | Buprenorphine HCl |
|---|---|
| Form | Injection |
| Strength | 0.3 mg/mL · 1 mL |
| NDC | 42023-179-05 |
| Marketing category | Rx only |
| Manufactured for | Endo USA, Malvern |
Reported in the same month (2026-06)
74 enforcement reports carry a report date in 2026-06; these 8 are the Class II ones nearest this record.
| Recall record | Recall number | Recalling firm | FDA tier | Reported |
|---|---|---|---|---|
| Alyacen 7/7/7, 0.5mg/0.035mg | D-0588-2026 | Glenmark Pharmaceuticals Inc., Usa | Class II | 2026-06-24 |
| VistaPharm, 25 Grams | D-0589-2026 | Pai Holdings LLC | Class II | 2026-06-24 |
| VistaPharm, 50 Grams | D-0590-2026 | Pai Holdings LLC | Class II | 2026-06-24 |
| VistaPharm, 25 Grams | D-0591-2026 | Pai Holdings LLC | Class II | 2026-06-24 |
| VistaPharm, 50 Grams | D-0592-2026 | Pai Holdings LLC | Class II | 2026-06-24 |
| Vasopressin 2 Units/2 mL in 0.9% Sodium Chloride | D-0593-2026 | Integradose Compounding Services LLC | Class II | 2026-06-24 |
| Aripiprazole Tablets USP, 30 mg | D-0594-2026 | Ajanta Pharma Usa Inc | Class II | 2026-06-24 |
| Pearson Quality Topical Anesthetic Gel (20% Benzocaine) | D-0600-2026 | Keystone Industries | Class II | 2026-06-24 |
Nearest Class II recalls by date
213 of 250 indexed records share the Class II tier; the 8 nearest to 2026-06-24 by report date are listed here.
| Recall record | Recall number | Recalling firm | Strength / form | Reported |
|---|---|---|---|---|
| Quala Dental Products, 20 % | D-0601-2026 | Keystone Industries | 20 % · Gel | 2026-06-24 |
| DHP Topical Anesthetic Gel, 20% | D-0602-2026 | Keystone Industries | 20% · Gel | 2026-06-24 |
| Burkhart topical anesthetic gel, 20 % | D-0603-2026 | Keystone Industries | 20 % · Gel | 2026-06-24 |
| Dental City TOPICAL ANESTHETIC GEL, 20% | D-0604-2026 | Keystone Industries | 20% · Gel | 2026-06-24 |
| PureLife, 20% | D-0605-2026 | Keystone Industries | 20% · Gel | 2026-06-24 |
| safco SensiCaine-Ultra (20% Benzocaine) | D-0606-2026 | Keystone Industries | 20% · Gel | 2026-06-24 |
| Chlorthalidone Tablets, 25 mg | D-0610-2026 | Inventia Healthcare Ltd | 25 mg · Tablets | 2026-06-24 |
| Lucky Super Soft, 1% | D-0629-2026 | Dabur India Ltd | 1% · Cream | 2026-06-24 |
Reading this record
Class II is the FDA's own severity tier for the recall action — 213 of the 250 indexed records carry it — and it describes the agency's assessment of the action, not a risk statement about any individual. Match a package against 42023-179-05 at the FDA source to confirm it is covered.
Namespace context: the Class II index (213 records) and the recall hub (250 records, 118 FDA events); Par Health Usa, LLC (3 indexed records) aggregates this firm across datasets.
Coverage and limits of this record
This page reflects the openFDA enforcement report for D-0596-2026 as ingested on 2026-08-22, which can lag the live FDA record and omits detail held only in primary documents. It offers no clinical assessment, no advice about whether to use any product, and no substitute. For any health question consult a qualified healthcare professional.
Source & provenance
- Official source
- https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0596-2026%22
- Source dataset
- openFDA Drug Enforcement API
- Publication date
- 2026-06-24
- Ingested
- 2026-08-22
- Record hash
4b682994153afa89
Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.